logo
2 Undervalued Healthcare Stocks Poised to Dominate the Next Decade

2 Undervalued Healthcare Stocks Poised to Dominate the Next Decade

Globe and Mail5 days ago
Key Points
Pfizer and Novo Nordisk have underperformed the market over the past year.
But both should remain major players in important areas within the pharma industry.
Investors could see the two drugmakers' shares beat the market over the next decade.
10 stocks we like better than Pfizer ›
Pharmaceutical giants Pfizer (NYSE: PFE) and Novo Nordisk (NYSE: NVO) have lagged the market over the past year, although Pfizer's poor performance dates back much further. Though these companies have encountered challenges, there are good reasons to be bullish on their long-term prospects.
Pfizer could become an even bigger player in the oncology market (the largest therapeutic area in the industry by sales) over the next decade, while Novo Nordisk will be a major player in diabetes and the fast-growing weight management space. Both could produce excellent results along the way. Here's the rundown.
1. Pfizer
Pfizer's financial results haven't been great in recent years. To make matters worse, the company will face important patent cliffs by the end of the decade. One of them will be for Eliquis, an anticoagulant that is still one of its best-selling medicines. However, Pfizer has prepared for that eventuality.
The company made several acquisitions and licensing deals that significantly boosted its pipeline, especially in oncology. Pfizer spent $43 billion to acquire Seagen, a smaller cancer specialist whose lineup and pipeline were impressive for a company of its size. With the financial and strategic backing of the larger company, it should yield even more key approvals in the field in the coming years.
Pfizer also recently made an up-front payment of $1.25 billion to China-based 3SBio for the rights to SSGJ-707, an investigational bispecific antibody, a portion of the oncology market that's gaining traction these days. 3SBio will be eligible for commercial and regulatory milestone payments of up to $4.8 billion, not including royalties.
These moves should eventually pay off for Pfizer and strengthen its position in oncology. The drugmaker plans to have eight blockbuster cancer medicines on the market by 2030, up from its current five, while doubling its reach from the current 1 million patients it serves. Of course, Pfizer isn't just a cancer play. The company's extensive pipeline should enable it to launch products in other areas and ultimately get back on track.
While its shares have been lagging the market significantly, that could change in the next decade as financial results rebound thanks to its innovative efforts. Pfizer's shares look especially attractive when considering its valuation. Its forward price-to-earnings (P/E) ratio is 8.7, much lower than the healthcare sector 's 15.8. From their current levels, Pfizer's shares could go on to generate excellent returns through 2035.
2. Novo Nordisk
Novo Nordisk pioneered the market for weight management medicines. However, Eli Lilly seems to have taken the lead in that field, at least for now. Novo Nordisk has faced some clinical setbacks, leading to a poor performance over the trailing-12-month period. Can the company rebound and perform well in the next decade? In my view, it can, and the market may be significantly undervaluing its potential.
Its sales of Wegovy, one of the top-selling anti-obesity medications, continue to grow rapidly. Novo Nordisk recently requested approval from the U.S. Food and Drug Administration for oral semaglutide (the active ingredient in Wegovy). That's good for patients who want a non-injected option, and helps counter Lilly's up-and-coming oral GLP-1 medicine, orforglipron.
Elsewhere, Novo Nordisk recently started phase 3 studies for amycretin, a next-gen weight loss candidate. Amycretin is being investigated in both oral and subcutaneous formulations, and both are currently in late-stage clinical trials.
The company also enhanced its pipeline through licensing deals, including one with United Biotechnology, a subsidiary of the China-based company United Laboratories International Holdings, for UBT251. This potential anti-obesity medicine mimics the actions of three gut hormones: GLP-1, GIP, and glucagon. The transaction cost Novo Nordisk an up-front payment of $200 million and up to $1.8 billion in milestone payments.
Thanks to all these developments, Novo Nordisk should remain a leader in weight management in the next decade. Even though competition is mounting, no drugmaker not named Eli Lilly has a lineup or a pipeline as deep as Novo Nordisk's. Furthermore, the Denmark-based pharmaceutical leader will also continue to dominate the diabetes market, as it has done for decades.
Novo Nordisk generates consistent revenue and earnings that typically grow faster than those of similarly-sized peers. Yet the stock's forward P/E is 16.7, which is slightly above the industry average. In my view, that's a bargain for a company that generates better-than-average results and has a deep pipeline in a fast-growing area -- not to mention two of the world's top 20 best-selling drugs, in Wegovy and Ozempic.
For investors willing to stay the course, Novo Nordisk's future still looks incredibly bright.
Should you invest $1,000 in Pfizer right now?
Before you buy stock in Pfizer, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!*
Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 15, 2025
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

The Best Artificial Intelligence (AI) Stock to Buy With the Market At All-Time Highs
The Best Artificial Intelligence (AI) Stock to Buy With the Market At All-Time Highs

Globe and Mail

time11 minutes ago

  • Globe and Mail

The Best Artificial Intelligence (AI) Stock to Buy With the Market At All-Time Highs

Key Points Alphabet stock is still trading at a cheap multiple. It has many growth vectors to benefit from artificial intelligence. Margin can help the company's profits explode in the next few years. These 10 stocks could mint the next wave of millionaires › The S&P 500 keeps soaring to new highs, making it feel impossible to find a cheap large-cap stock to buy today. This is especially true in technology and artificial intelligence (AI). Stocks such as Nvidia and Microsoft have price-to-earnings (P/E) ratios approaching 40 or higher, making them risky for investors. Growth expectations are high for many companies, which can make it increasingly difficult to buy stocks for your investment portfolio, especially if you care about value investing. That isn't the case with every AI stock. Here's why Alphabet (NASDAQ: GOOG)(NASDAQ: GOOGL) is the one AI stock you can buy right now with stocks at all-time highs. Alphabet's matrix of growth Some pundits have deemed Alphabet -- parent company of Google -- an AI loser because of competition from ChatGPT. I think this underplays the big picture. Alphabet has perhaps the most to gain from AI through its various subsidiaries, while also employing the best data advantage of any big technology player because of all the user data from Google, YouTube, and other properties. AI is not going to eliminate Google Search -- it will take it to the next level. AI overviews are already growing like a weed for Google Search results, while the Gemini chatbot is helping with advanced conversational queries. An explosion in new AI technologies will greatly expand the addressable market for Google and its related properties. That's why revenue is growing at a 10% annual rate for Google Services, even though it generated $77 billion in revenue just in the first quarter. Another way Alphabet can benefit from AI demand is Google Cloud, which is growing revenue at an astonishing 28% year-over-year clip, and is close to surpassing $50 billion in annualized revenue (it may surpass that mark next quarter). AI workloads will need huge amounts of specialized computing power to function, which Google Cloud is set to provide. Let's not forget self-driving start-up Waymo, which is taking over the streets of America's big cities, using Alphabet's infrastructure, engineering, and AI expertise. It is an entire matrix of growth for Alphabet that can be supercharged by AI. Profit margin expansion? AI requires a lot of upfront spending on data centers and computer chips in order to train and operate. Alphabet is planning to spend $75 billion on capital expenditures in 2025, mostly related to AI. This will increase depreciation and require steady growth in order to get a return on this investment, which some investors are skeptical about. Google Cloud used to be unprofitable, but it posted an 18% operating margin last quarter, a number that can keep expanding as it reaches larger scale. Due to these factors plus better hiring efficiency employed by Alphabet coming out of the pandemic, I think Alphabet's profit margins are set to keep inching higher over the next few years. Its operating margin recently hit a record of 33%. With huge operating leverage on its fixed-cost investments, I think this figure can grow to 40% over the long term, which is similar to Microsoft. With revenue at $359 billion that could grow to $400 billion or even $500 billion within a decade, a 40% operating margin could help Alphabet grow its operating income to $200 billion within a few years. That would make it the most profitable company in the world. GOOG PE Ratio data by YCharts. Buybacks and a cheap stock With all the earnings flowing to its balance sheet, Alphabet is returning capital to shareholders through buybacks and dividends. It pays a dividend yielding 0.42% that is set to grow steadily, while shares outstanding have fallen by 12% in the last 10 years. Alphabet plans to keep repurchasing stock at these cheap prices. It has a P/E ratio of 21, which is the cheapest among the " Magnificent Seven" stocks. This is shocking to see, given how much Alphabet can benefit from AI and cloud computing growth. Add everything up, and Alphabet looks like a fantastic stock to buy today, even with the market at all-time highs. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,040%* — a market-crushing outperformance compared to 182% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of July 21, 2025

CGTN: President Xi Jinping calls on China, EU to provide more stability, certainty for world
CGTN: President Xi Jinping calls on China, EU to provide more stability, certainty for world

Toronto Star

time2 hours ago

  • Toronto Star

CGTN: President Xi Jinping calls on China, EU to provide more stability, certainty for world

Chinese President Xi Jinping met with European Union leaders during their visit to Beijing for the 25th China-EU Summit on Thursday. CGTN published an article exploring China-EU relations in two-way trade and investment, emphasizing the need for both sides to embrace multilateralism, openness and cooperation to bring greater stability and certainty to the world. BEIJING, July 26, 2025 (GLOBE NEWSWIRE) — Fifty years ago, China-Europe trade was a trickle. Now, as the two sides mark half a century of ties, a single day's trade equals what they exchanged in the entire year when relations were first established.

Barclays Remains a Buy on Lloyds Banking (LLOY)
Barclays Remains a Buy on Lloyds Banking (LLOY)

Globe and Mail

time2 hours ago

  • Globe and Mail

Barclays Remains a Buy on Lloyds Banking (LLOY)

Barclays analyst maintained a Buy rating on Lloyds Banking today and set a price target of £0.90. The company's shares closed yesterday at p78.04. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Rakkar is a 5-star analyst with an average return of 25.9% and an 81.56% success rate. Rakkar covers the Financial sector, focusing on stocks such as Lloyds Banking, HSBC Holdings, and Standard Chartered. In addition to Barclays, Lloyds Banking also received a Buy from TR | OpenAI – 4o's Wes Branchor in a report issued yesterday. However, on the same day, Bank of America Securities maintained a Hold rating on Lloyds Banking (LSE: LLOY). The company has a one-year high of p79.19 and a one-year low of p47.43. Currently, Lloyds Banking has an average volume of 126.2M. Based on the recent corporate insider activity of 117 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LLOY in relation to earlier this year.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store